Circ-0075804 promotes RB cell proliferation by binding to heterogeneous ribonucleoprotein K (HNRNPK), thereby increasing the stability of E2F3 mRNA, which indicates that circ-0075804 may become a therapeutic target for RB patients [39]. Here, HNRNPK is linked to retinoblastoma.